LGHT vs. ARKG ETF Comparison

Comparison of Langar Global HealthTech ETF (LGHT) to ARK Genomic Revolution Multi-Sector ETF (ARKG)
LGHT

Langar Global HealthTech ETF

LGHT Description

LGHT targets the global healthcare technology industry. The fund actively invests in HealthTech companies, which the adviser defines as firms that develop technology designed to create healthcare efficiency by addressing key pain points for patients, providers, payors, and hospitals, including those companies that derive a majority of their revenue from HealthTech products and services. The portfolio construction starts by identifying companies that fit into the advisers HealthTech definition. The remaining companies are screened using a proprietary metric that assesses each firms financial health, involvement in relevant controversies, as well as the strength of its team and culture. Each company is then assigned an industry risk score through an algorithm that defines quantitative and qualitative risk categories and weights them accordingly. Finally, each company is reviewed by an investment committee. However, the portfolio manager still has full discretion over the final selection.

Grade (RS Rating)

Last Trade

$10.31

Average Daily Volume

913

Number of Holdings *

31

* may have additional holdings in another (foreign) market
ARKG

ARK Genomic Revolution Multi-Sector ETF

ARKG Description Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.

Grade (RS Rating)

Last Trade

$23.40

Average Daily Volume

2,216,483

Number of Holdings *

34

* may have additional holdings in another (foreign) market
Performance
Period LGHT ARKG
30 Days -3.06% -4.11%
60 Days -2.46% -11.01%
90 Days -0.81% -10.33%
12 Months -13.96%
4 Overlapping Holdings
Symbol Grade Weight in LGHT Weight in ARKG Overlap
ACCD F 0.07% 1.47% 0.07%
MRNA F 1.72% 0.01% 0.01%
SDGR C 0.21% 4.14% 0.21%
VEEV C 5.15% 1.7% 1.7%
LGHT Overweight 27 Positions Relative to ARKG
Symbol Grade Weight
ISRG A 15.39%
GEHC C 8.56%
RMD C 6.71%
IQV F 6.34%
DXCM C 5.51%
PODD B 5.26%
PHG C 4.87%
ZBH C 3.57%
BNTX D 3.53%
ALGN D 2.85%
MASI B 2.46%
DOCS C 2.06%
PRCT B 1.27%
ALKS C 0.66%
TNDM D 0.54%
IRTC C 0.44%
PRVA C 0.44%
OMCL C 0.42%
LFST C 0.31%
TDOC C 0.28%
PGNY F 0.25%
EVH F 0.22%
GDRX F 0.2%
ALHC C 0.2%
PHR F 0.17%
MODV C 0.03%
TBRG A 0.03%
LGHT Underweight 30 Positions Relative to ARKG
Symbol Grade Weight
TWST F -8.37%
RXRX D -7.42%
CRSP D -7.34%
ADPT C -5.03%
CDNA D -4.77%
VCYT B -4.51%
BEAM D -4.01%
NTLA F -3.89%
IONS F -3.85%
NTRA A -3.82%
NRIX C -3.78%
TXG F -3.56%
GH B -3.49%
ARCT F -3.19%
PSNL D -2.7%
ABSI F -2.19%
PACB D -2.16%
BFLY A -1.71%
AMGN D -1.68%
VRTX D -1.29%
ILMN C -1.25%
CERS D -1.18%
INCY C -1.11%
REGN F -0.92%
PRME F -0.9%
CMPS F -0.75%
MASS F -0.69%
QSI B -0.68%
EXAS D -0.65%
RPTX F -0.64%
Compare ETFs